To look into the relation between parathyroid hormone and abnormal glucose homeostasis in chronic renal failure patients on regular hemodialysis. Methods 41 subjects, with chronic renal failure, and on regular hemodialysis (28 male, 13 female; age range 19-64 years). Full history and clinical examination were taken for every patient. In addition, ten age and sex matched healthy persons were selected randomly as control group. Informed consent was obtained. All patients were investigated to determine serum creatinine, calcium, phosphorus, alkaline phosphatase, parathyroid hormone, fasting glucose, and fasting insulin. Homeostasis module assessment of insulin resistance was calculated as a measure of insulin resistance, Homeostasis module assessment of beta cell was calculated as a measure of pancreatic beta cell function. The uremic patients were classified into two groups: group A included 24 patients with plasma parathyroid hormone levels < 450 pg/ ml and group B included 17 patients with plasma parathyroid hormone level 450 pg/ml. Results There is a marked increase in fasting insulin level in all patients versus control associated with increased homeostasis module assessment of insulin resistance, an index for insulin resistance. Significant negative correlation is found between parathyroid hormone and fasting insulin and homeostasis module assessment of insulin resistance in uremic patients. Patients with severe hyperparathyroidism have relatively more impaired pancreatic beta cell function in comparison to those with mild hyperparathyroidism. The pulsed dose of intravenous 1-cholecalciferol is associated with low parathormone level and high serum calcium. Conclusion Insulin resistance is a constant feature of chronic renal failure patients under hemodialysis therapy, while secondary hyperparathyroidism is linked negatively to beta cell function. Intermittent pulsed intravenous alphacalcidol is an effective method of lowering high serum parathyroid hormone and is associated with improvement of beta cell function without significant effect on insulin resistance.
Introduction
hronic renal failure is a major health problem in Egypt, and the number of patients on regular hemodialysis is increasing nowadays. At the same time, its different lines of therapy (conservative, dialysis, and transplantation) open wide hopes for long term survival of uremic patients. Increased secretion of parathyroid hormone (PTH) is common in patients with chronic renal failure, and the excess blood levels of PTH could be deleterious to many organ systems 1 . A variety of symptoms and signs including encephalopathy, neuropathy, dialysis dementia, reduced left ventricular ejection fraction, impaired insulin secretion, glucose intolerance, hyperlipidaemia, soft tissue calcification, bone resorption, pruritis, immunological disturbances, and sexual dysfunction are encountered in patients with uremia 2 .
These manifestations contribute to the uremic syndrome and at least part of their pathogenesis has been attributed to PTH as a uremic toxin, and it is thought that such actions of PTH are mediated by an increase in intracellular calcium 2 . Uremic patients are thought to be insulin resistant and about half of them were found to have impaired glucose tolerance 3 . The insulin resistance is a characteristic feature of uremic patients; a problem that could be partially ameliorated both by hemodialysis and by the chronic ambulatory peritoneal dialysis 4, 5 . Some evidences suggest a role for PTH in the pathogenesis of deranged beta cell function of uremia. Early studies reported that PTH has a role in the problem of insulin resistance 6 . Subsequent investigations using clamp techniques demonstrated that the development of glucose intolerance in uremic dogs could be prevented by parathyroidectomy 7 .
Administration of PTH to rats with normal renal function increased the resting cytosolic calcium, decreased the ATP content and impaired insulin release through ATP-dependent Kchannels 8 . Pancreatic islets are apparently a PTH target; PTH stimulates cAMP production and possibly also protein kinase C in a calcium-dependent fashion 9 . Also, it was suggested that uremic patients with elevated serum PTH were found to be severely insulin resistant and hyperinsulinemic and intravenous vitamin D treatment led to a significant reduction of serum PTH levels and to complete normalization of insulin sensitivity in hemodialysis patients 10 . However, the exact effect of hyperparathyroidism on different parameters of glucose homeostasis, and the effect of lowering serum PTH by one alpha hydroxycholecalciferol therapy still need further evaluation. It is theoretically possible that the deficiency of 1,25 (OH)2D3 commonly encountered in patients with CRF plays a role in the impaired insulin secretion encountered in these patients 11 . The aim of the study is to look into the relation between serum PTH and parameters of glucose homeostasis and to analyze the effect of lowering PTH on these parameters.
Materials and Methods
The present study was conducted on forty one subjects suffering from chronic renal failure due to different intrinsic renal causes C In addition, 10 healthy volunteers age and sex matched selected randomly as a reference (control) group. Informed consents were obtained from all subjects (patients and control) in the study. All persons of the study were subjected to full laboratory investigation to determine serum creatinine, calcium, phosphorus, alkaline phosphatase, PTH, blood hemoglobin, fasting glucose, and fasting insulin. HOMA-IR was calculated as a measurement of insulin resistance, also HOMA-B was calculated as a measurement of pancreatic beta cell function. The patients were classified into two groups according to plasma PTH level. Group A; included patients with plasma PTH level less than 450 pg/ml. This group included 24 patients 15 males and 9 females. Group B; included patients with plasma PTH level more than 450 pg/ml. This group included 17 patients 13 males and 4 females. Ten patients from those of group B have been selected randomly to receive pulsed doses of one alpha-cholecalciferol in the form of 1 microgram I.V. thrice weekly at the end of the hemodialysis session for four consecutive months. After the termination of the pulsed dose of one alphacholecalciferol, the patients were returned back to their oral dose of 1 -cholecalciferol.
Complete laboratory investigations were performed for all the patients and the control at the beginning of the study, and four months later after termination of the pulsed dose of 1 -cholecalciferol for all patients who received the pulsed dosage of 1 -cholecalciferol. Insulin resistance was measured using HOMA-IR test, while, pancreatic beta cell function was measured using HOMA-B test which were measured according as follows 12 
Results
The detail of the results recorded in this study is outlined in Tables 1-5 . Further interpretation of the results and data comparison is mentioned in the discussion.
Discussion
Abnormal glucose homeostasis has been a well known feature of uremic patients for many years. Several studies demonstrated the presence of insulin resistance and impaired glucose tolerance in uremic patients 13, 14 . Others demonstrated pancreatic beta cell dysfunction in uremia 14, 15 . The problem of abnormal glucose homeostasis may be responsible for the increased incidence of atherosclerosis and cardiovascular morbidity in uremic patients 16 , which can account for high mortality rates in these patients. Patients with chronic renal failure (CRF) in 
Statistical analysis
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the current work have significantly lower serum calcium, and significantly higher serum phosphorus than that of the control group. These changes reflect well-known problems in CRF that were previously reported 17 . This denotes that although these patients were under hemodialysis therapy, they were far from being ideally controlled. The predialysis serum creatinine was greatly increased. The higher serum PTH in the uremic patients indicates the well known major problem affecting these patients which is a secondary hyperparathyroidism in CRF patients 18 . Since the reduced PTH degradation and clearance affect mainly the inactive PTH fragments, it is unlikely to cause alternation in the intact PTH steady state concentration 19 . Therefore, uremic hyperparathyroidism is mainly due to an increase in bioactive PTH synthesis and a release by the parathyroid gland.
The stimulatory factors of parathyroid hormone synthesis and secretion include hypocalcaemia, hyperphosphatemia, and vitamin D3 metabolic abnormalities 20 . Thus, there are additional factors that may contribute to hyperparathyroidism in chronic renal failure as acidosis and uremic toxins 21 . Increased fasting insulin in uremic patients can be attributed to decrease in the metabolic clearance of insulin 22 . Impaired degradation of insulin in non-renal tissues (liver and muscle) may also contribute to the prolonged half life of insulin in uremic patients 22 . This increase in fasting insulin is not associated with any significant change in fasting blood glucose that may give an impression of resistance to the action of insulin. Moreover, the higher HOMA-IR value in CRF documents the presence of insulin resistance in CRF patients in the present work. These results are consistent with the study of Tuzeu et al 23 , who demonstrated that mean insulin level is significantly elevated in uremic patients versus control group, and also, demonstrated insulin resistance in the uremic patients of the study using HOMA-IR as a measurement of insulin resistance. Also, these results are in accord with those of Sechi et al 24 who reported that the problem of insulin resistance is found in uremic patients and even in early renal impairment; alternation of glucose metabolism became evident only when creatinine clearance was < 50ml/min. A multitude of many previous studies reported insulin resistance in uremic patients 6, 25, 26 . Many factors contribute to the problem of insulin resistance in uremia. Accumulation of some uremic toxin(s) may be responsible Several studies demonstrated that anemia is a major pathogenic factor behind insulin resistance in chronic renal failure 30 . Spaia and his co-workers 30 proved the beneficial effect of EPO treatment on insulin resistance in dialysis patients. Tuzeu and his co-workers 23 demonstrated that correction of anemia using erythropoietin normalized insulin sensitivity in uremia. Furthermore, they demonstrated that improvement in insulin sensitivity is positively correlated with duration of EPO therapy. Plasma cell differentiation antigen 1 (PC-1) is an inhibitor of insulin receptor tyrosine kinase and it is thought to be one of the factors behind insulin resistance in uremia 31 . Stevanovic and his co-workers 32 found increased lymphocyte PC-1 activity in uremic patients over the control, and two months after EPO therapy, lymphocyte PC-1 activity decreased significantly, suggesting that an effect of PC-1 expression could be implicated in the amelioration of insulin resistance in uremic patients. The uremic patients have more insulin resistance in moderate anemia than mild anemia. This may be due to the fact that some of them have been under EPO therapy while others received frequent blood transfusion. Moreover, in contrast to the previous study of Mak 28 . There is no significant correlation between hemoglobin level and any of the parameters of glucose homeostasis in the present work. This may be attributed to the observation that many patients were already receiving EPO therapy and that the degree of anemia is much less than that reported in the previous studies before correction. Lindall and his co-workers 7 reported that uremic patients on hemodialysis with normal PTH levels had a normal insulin response to I.V glucose, while those with hyperparathyroidism showed disturbed insulin responses which was normalized after parathyroidectomy. The negative correlation between serum PTH and fasting insulin and HOMA-B (an indicator of beta cell function) and HOMA-IR index (a marker of insulin resistance), denote that PTH has an ameliorating effect on insulin resistance or, in other words, it is at least not linked to the worsening of insulin resistance. This is in obvious contrast with previously cited researches 7, 33 demonstrating the role of PTH in the problem of insulin resistance. The patients with severe hyperparathyroidism (HPT) have significantly low HOMA-B than those patients with moderate HPT. This may denote that the higher PTH level may have a deleterious effect on beta cell function. In our study, the intravenous pulsed alphacalcidol thrice weekly resulted in significant increase in serum calcium and improve the beta cell function (measured by HOMA-B). Whether these changes were due to lowering the PTH or an intrinsic effect of alphacalcidol or increased serum calcium level is open to speculations. Lindall 7 , Prager 33 , Amend 34, and their coworkers studied insulin resistance using insulin tolerance tests in six stable uremic patients with secondary hyperparathyroidism prior to and after subtotal parathyroidectomy, the authors found that parathyroidectomy per se had no significant effect upon glucose utilization, or the resistance of the peripheral tissues to the action of exogenous insulin. This agrees with the finding of the present work of absence of significant improvement of insulin resistance after lowering PTH with I.V. alphacalcidol. Mak 35 , Akmal 8 , and their co-workers studied the effect of PTH on glucose homeostasis using the hyperglycemic clamp technique in eight uremic children, and they found that lowering of PTH using high-dose phosphate binders and dietary restriction of phosphate led to improvement in pancreatic beta cell function and was not associated with any improvement in insulin resistance of the uremic children. Also, Mak and his co-workers 28 , used the hyperglycemic clamp studies to study insulin sensitivity in eight uremic patients. They demonstrated a negative correlation between glucose metabolic rate (a measure of insulin sensitivity) and PTH level, but this was possibly ascribed to the effect of changing the GFR with serum PTH level. The authors also, demonstrated that correction of hyperparathyroidism by subtotal parathyroidectomy did not improve the problem of insulin resistance in the parathyroidectomized uremic patients. Moreover, lowering of PTH by subtotal parathyroidectomy was associated with increased insulin secretion from pancreatic beta cells with amelioration of glucose tolerance 27 , which is consistent with the results of the present study. Furthermore, the observation of negative relation between PTH and beta cell function is consistent with the study of Fadda and his co-workers 37 demonstrated that, excess PTH is responsible for the decreased insulin secretion by pancreatic beta cells. They found that, insulin secretion in parathyroidectomized uremic rats was better than the control uremic rats. They also demonstrated that PTH administration to non uremic normal rats decreased insulin release by the islets. published data indicate that excess PTH in uremia is associated with increased basal levels of calcium in many cells including pancreas 15, 37 . Elevated basal level of calcium of pancreatic beta cells appears to be responsible for decreased insulin secretion in secondary hyperparathyroidism in CRF through reducing intracellular ATP content of the cells which is important in the process of insulin secretion. This is because ATP facilitates the closure of the ATPdependent potassium channels, which is followed by cell depolarization and subsequent activation of voltage-sensitive calcium channels 38 . This was supported by Missry 13 who demonstrated that the glucose-induced calcium signals from CRF rats was significantly smaller than that observed in islets from normal rats. The present results suggest that one alpha calcidol increased fasting insulin, and improved pancreatic beta cell functions. This is in harmony with previous studies 39, 40 which showed the effect of one alpha cholecalciferol on glucose homeostasis using the hyperglycemic clamp techniques in eleven uremic patients. That study reported that acute intravenous 1-alpha cholecalciferol increased insulin secretion and corrected glucose intolerance in uremic patients. But in contrast to our results, this increase in insulin secretion was not associated with any significant changes in PTH level or, ionized or total calcium. This demonstrates that one alpha cholecalciferol, appears to be a direct modulator of insulin release from the pancreatic beta cell in uremia independent of PTH and serum electrolyte concentrations. Available data indicate that pancreatic beta cells have a specific receptor protein for 1, 25(OH)2D3 41 . They found, in the chick, that the pancreatic islets possess receptor proteins for 1, 25(OH)2D3 through which it interacts with the pancreatic islets and modulates their insulin secretion. Likewise, it is still premature to confirm whether PTH modulation and vitamin D3 has a role in insulin resistance or insulin secretion and whether it acts through lowering PTH or through another different mechanism inherent to this molecule 42,43 . In conclusion, hyperparathyroidism, insulin resistance, and beta cell dysfunction are common problems in CRF patients on hemodialysis.
The excess PTH is significantly associated with beta cell dysfunction. Effective lowering of serum PTH by intravenous pulsed one alpha cholecalciferol or subtotal parathyroidectomy can achieve better beta cell function but may not help the problem of insulin resistance. It is recommended that all CRF patients are investigated regarding glucose intolerance, insulin resistance, and beta cell function. Any drugs or chemicals that may deteriorate glucose tolerance should be avoided if possible. Using drugs that may improve insulin resistance and beta cell function can be beneficial to some cases; but this awaits further longitudinal studies.
